Introduction
Triple-negative breast cancer (TNBC) is a unique subtype of breast cancer that is histologically defined by the absence of the estrogen receptor (ER), progesterone receptor (PR) and lack of human epidermal growth factor receptor 2 (Her2) overexpression (1, 2) . TNBC is often a highly invasive and metastatic form of breast cancer with an overall poorer prognosis compared with other breast cancer subtypes. This is partly due to TNBC usually displaying more aggressive behavior and lacking effective targeted therapies (3, 4) . Chemotherapy is currently the only treatment option for metastatic TNBC and is only effective at the initial treatment stage (5, 6) . There is an urgent need to better understand the underlying mechanism of TNBC aggressive behavior and identify novel targets for developing more efficient therapies for TNBC.
MicroRNAs (miRNAs) are a large class of small non-coding RNAs and regulate gene expression through binding to the 3′ untranslated region (3′UTR) of their target mRNAs, resulting in mRNA degradation or translation inhibition (7, 8) . miRNAs are found to be critically involved in many fundamental processes of cancer (8, 9) , although the underlying mechanisms have not been well understood for the majority of miRNAs. In breast cancer, miRNAs are shown to affect cancer cell survival, proliferation, differentiation, migration, invasion and metastasis (10) (11) (12) . However, fewer studies on the role of miRNAs in TNBC have been done compared with other breast cancer subtypes. Further studying miRNA function in TNBC may lead to identification of novel therapeutic targets for TNBC.
Human miRNA-200 (miR-200) family consists of five members divided into two groups: the miR-200b/-200a/-429 group located on chromosome 1 and the miR-200c/-141 group located on chromosome 12 (13, 14) . Alternatively, the miR-200 family can be classified into two functional clusters based on the identities of their seed sequences: the miR-200b/-c/-429 cluster and the miR-200a/-141 cluster. The miR-200 family members are among the first miRNAs reported to function as potent inhibitors of epithelial-to-mesenchymal transition (EMT) and as regulators of epithelial plasticity of cancer by directly targeting EMTinducing transcription factors zinc-finger E-box-binding homeobox factor 1 (ZEB1) and 2 (ZEB2; [15] [16] [17] [18] [19] [20] [21] . Despite its well-established role in inhibiting EMT (15) (16) (17) (18) (19) , a process thought to be important in cancer metastasis (22) , the effect of miR-200 family on cancer metastasis has been shown to be controversial. Ectopic expression of either one group of miR-200 or the entire miR-200 family in cancer cells is able to suppress (23) or promote cancer metastasis (24, 25) . Moreover, relatively few studies have been done on the effect of a single member of miR-200 family on cancer metastasis. In addition, the mechanism of miR-200 function has not been well understood and only a limited number of miR-200 target genes that promote cell migration and cancer metastasis have been identified (26) (27) (28) . It is essential to further investigate the effect of miR-200 family on cancer metastasis and identify their new targets that play crucial roles in cancer metastasis.
Protein kinase Cα (PKCα) is a member of PKC family of serine/ threonine kinases containing 10 isozymes, playing important roles in regulating cell migration and cancer metastasis (29, 30) . Particularly, recent studies revealed that PKCα functions as a central signaling node in breast cancer stem cells and has been proposed to be a valuable therapeutic target for certain breast cancer subtypes (31, 32) . Moreover, recent studies also showed that high PKCα levels were most commonly detected in high-grade TNBC tumors (32, 33) . However, little is known about the mechanism of PKCα dysregulation in breast cancer.
In this study, we identified PKCα as a new direct target of miR200b and showed that miR-200b suppresses TNBC cell migration and metastasis by targeting PKCα, which in turn reduces Rac1 activation. The findings from this study not only provide mechanistic insights for recent observations showing that metastatic TNBC tumors have high PKCα levels, but also suggest that miR-200b and PKCα may serve as promising therapeutic targets for metastatic TNBC. MCF-7, T-47D, BT-474, MDA-MB-453, SKBR-3, MDA-MB-468, BT-20,  Hs578T and BT-549 cell lines were purchased from and validated by American Type Culture Collection (ATCC, Manassas, VA). These cells were cultured Abbreviations: DAPI, 4′,6-diamidino-2-phenylindole; EMT, epithelial-tomesenchymal transition; ER, estrogen receptor; GFP, green fluorescent protein; H&E staning, hematoxylin and eosin; Her2, human epidermal growth factor receptor 2; miRNAs, MicroRNAs; miR-200, microRNA-200; PKCα, protein kinase Cα; Q-PCR, quantitative PCR; shRNA, short hairpin RNA; TNBC, triple-negative breast cancer; UTR, untranslated region; ZEB1, zincfinger E-box-binding homeobox factor 1; ZEB2, zinc-finger E-box-binding homeobox factor 2. Quantitative PCR analysis Cellular total RNAs were extracted using QIAGEN miRNeasy mini kit (Valencia, CA) for quantitative PCR (Q-PCR) analysis, which was carried out in ABI 7500 Fast Real-Time PCR System using TaqMan gene expression assays for the miR-200 family (Applied Biosystems, Foster City, CA). U6 snRNA was used to normalize relative miR-200 expression levels as described previously (34) .
Materials and methods

Cell lines and cell culture
Generation of miR-200b stably expressing cell lines
Vector control (green fluorescent protein, GFP) and miR-200b stably expressing cells were generated by transducing cells with control (pMIRNA-GFP) or miR-200b precursor-expressing (pMIRNA-GFP-200b) lentiviral particles (System Biosciences, Mountain View, CA), respectively, as described previously (34) . The miR-200b stably expressing cell clones were selected by Q-PCR analysis of miR-200b levels in clones grown from series dilution culture of cells transduced with miR-200b precursor-expressing lentiviral particles.
Generation of miR-200b and PKCα double stably expressing cells
Human PKCα full-length complementary DNAs lacking the 3′UTR was purchased from OriGene Technologies (Rockville, MD) and cloned into pLenti6.3⁄V5-DEST™ vector (Invitrogen) following the manufacturer's instructions. Vector control (pLenti6.3) and PKCα-expressing (pLenti6.3-PKCα) lentiviral particles were packaged as described previously (35) . To establish vector control, miR-200b and PKCα double stably expressing cells, miR-200b stably expressing cells were transduced with vector control (pLenti6.3) or PKCα-expressing (pLenti6.3-PKCα) lentiviral particles, respectively, and selected with Blasticidin.
Generation of PKCα shRNA stable knockdown cells
Vector control and PKCα stable knockdown cells were generated by transducing cells with control (pLKO.1-puro) or PKCα short hairpin RNA (shRNA) expressing (pLKO.1-puro-PKCα-shRNA) lentiviral particles, respectively. The control and PKCα shRNA lentiviral constructs were purchased from Sigma (St Louis, MO) and the lentiviral particles were packaged as described previously (35) . Cells were transduced with vector control or PKCα shRNAexpressing lentiviral particles and selected with puromycin.
Generation of PKCα 3′UTR luciferase reporter wild-type and mutant-type vectors and dual luciferase reporter assays
A fragment of human PKCα 3′UTR containing nucleotide 1-1825 was synthesized by Blue Heron Biotech (Bothell, WA) and cloned into pMirTarget vector (OriGene Technologies), which served as the wild-type PKCα 3′UTR luciferase vector containing the miR-200b putative binding site. To generate the mutant-type PKCα 3′UTR luciferase vector, the same fragment of PKCα 3′UTR was synthesized with the miR-200b putative binding site completely mutated. The mutated PKCα 3′UTR fragment was similarly cloned into pMirTarget, which served as the mutant-type PKCα 3′UTR luciferase vector. Dual luciferase reporter assays were performed as described previously (34) . The relative luciferase reporter activity was calculated as the ratio of the wild-type or mutant-type PKCα 3′UTR firefly luciferase activity divided by the Renilla luciferase activity.
Wound healing and Transwell cell migration assays
Cell migration was determined by a wound healing assay and/or Transwell cell migration assay as described previously (36) . A proliferation inhibitor mitomycin C (1 µg/ml) (Sigma) and GO6976 (1 µM) (Tocris Bioscience, Bristol) were added into the medium when the wound was created.
Orthotopic mouse mammary xenograft tumor model studies
Six-week-old female nude mice (Nu/Nu, Charles River Laboratories) were used and maintained under regulated pathogen-free conditions. Animal protocols were reviewed and approved by the Michigan State University Institutional Animal Care and Use Committee. 
Immunohistochemistry and immunofluorescence staining of mouse mammary tumor and lung sections
Mouse mammary tumor and lung sections were prepared and subjected to H&E staining as described previously (37) . The immunohistochemistry staining of 5-bromo-2′-deoxyuridine in mammary tumor sections was carried out using the ABC kit from Vector Laboratories (Burlingame, CA) as described previously (37) . The presence of GFP in mouse lung sections was determined by performing GFP immunohistochemistry or immunofluorescence staining, or by staining sections with 4′,6-diamidino-2-phenylindole (DAPI) followed by directly viewing GFP fluorescence under a fluorescence microscope (Nikon Eclipse TE2000-U, Nikon, Melville, NY). The captured GFP fluorescent images were overlaid with the blue fluorescent images (nucleus DAPI staining) using MetaMorph software.
Western blot analysis
Cells were lysed using Tris-sodium dodecyl sulfate and sodium dodecyl sulfate-polyacrylamide gel electorphoresis was used as described previously (34) . These primary antibodies were used: anti-ZEB1, anti-E-cadherin, anti-PKCα (Cell Signaling Technology, Danvers, MA), anti-PKCβI (Santa Cruz Biotechnology, Santa Cruz, CA), anti-Rac1 (Millipore, Temecula, CA) and anti-β-Actin (Sigma).
Rac1-GTP pulldown assay
Rac1-GTP pulldown assays were carried out to analyze active Rac1 levels following previously described protocol (38) . Rac1-GTP levels were quantified using ImageJ software and the quantifications are presented as the relative Rac1-GTP levels (ratio of Rac1-GTP levels divided by the corresponding total Rac1 levels).
MTT assay and soft agar colony formation assay
The tetrazolium dye colorimetric test (MTT assay) was used to measure cell growth indirectly. Briefly, cells were cultured in 96-well plates (3-5 × 10 4 cells/well in 100 μl of complete culture medium) for 24, 48, or 72 h, respectively. At the end of culture, 50 μl of the MTT reagent (5 mg/ml) was added to each well and incubated for 4 h. Then, 200 μl of dimethyl sulfoxide was added to each well and incubated for another hour. The plate was read using a microplate reader (SpectraMAX Plus, Molecular Devices, Sunnyvale, CA) at a wavelength of 570 nm. Soft agar colony formation assay was performed as described previously (34) . Colony formation in the agar was photographed and counted (if >100 µm) under a phase-contrast microscope after 4 week incubation.
Statistical analysis
The statistical analyses for the significance of differences in numerical data (mean ± SD) were carried out by testing different treatment effects via analysis of variance (ANOVA) using a general linear model [Statistical Analysis System (SAS) version 9.1, SAS Institute, Cary, NC]. Differences between treatment groups were determined using a two sample t-test. A P value of <0.05 was considered statistically significant.
Results
The miR-200 family levels are extremely low in basal mesenchymallike TNBC cells and metastatic TNBC tumors and are inversely correlated with TNBC cell migratory abilities
Although abnormal expression of miR-200 family has been observed in various types of cancers (26) (27) (28) , their expression levels among different kinds of breast cancer cells and different subtypes of breast tumors are not well known. We first determined miR-200 family levels among 12 kinds of breast cancer cells. The basic features of these commonly used breast cancer cell lines were described previously (39) . Basal epithelial-like TNBC cells display a differentiated and epithelial-like morphology and express high levels of E-cadherin (data not shown). In contrast, basal mesenchymal-like TNBC cells exhibit a fibroblast-like morphology and their E-cadherin expression is undetectable by western blot (data not shown). We examined and compared the migratory capabilities of different kinds of TNBC cells using a wound healing assay. As shown in Figure 1B Figure 2B and C) . Moreover, the presence of GFP in lung sections was further demonstrated by directly viewing GFP fluorescence under a fluorescence microscope ( Figure 2D ). Together, these results indicate that stably expressing miR-200b is able to suppress mouse mammary xenograft tumor lung micrometastasis.
PKCα is a direct target of miR-200b
We next wanted to investigate the underlying mechanism of miR-200b suppressing TNBC cell migration and tumor metastasis. Previous studies showed that EMT-inducing transcription factors ZEB1 and ZEB2 are direct targets of miR-200 family (15) (16) (17) (18) (19) , implying that downregulation of ZEB1/2 by miR-200 may play an important role in its inhibitory effect on metastasis. However, a recent study reported that ZEB1 knockdown marginally reduces TNBC cell migration and that miR-200 could repress tumor metastasis through ZEB1-independent mechanisms (40) . To identify miR-200b new targets that may play crucial roles in its inhibitory effect on TNBC cell migration and tumor metastasis, we performed a bioinformatic analysis. Among the predicted targets of miR-200b, we are particularly interested in PKCα based on recent studies showing its critical role in regulating breast cancer cell stemness, mouse mammary tumor metastasis and the association of its expression with high grade of TNBC (31) (32) (33) . We first compared the expression levels of PKCα among 12 kinds of breast cancer cells. Western blot analysis showed that PKCα protein levels are remarkably higher in basal mesenchymal-like highly migratory TNBC cells than the weakly migratory ER+, Her2+ and basal epithelial-like TNBC cells ( Figure 3A) , which is inversely correlated with miR-200b levels among these cells ( Figure 1A) . Moreover, re-expressing miR-200b in basal mesenchymal-like TNBC cells drastically reduces the protein level of PKCα ( Figure 3B ) but has no effect on the levels of other PKC isozymes (Supplementary Figure 6 , available at Carcinogenesis Online).
A putative conserved binding site for miR-200b at nucleotide position 1319-1325 of human PKCα 3′UTR is predicted by two miRNA target-predicting software (TargetScan and DIANA-MICROT). We then generated the wild-type and mutant-type of PKCα 3′UTR luciferase reporter vectors. Dual luciferase reporter assays showed that re-expressing miR-200b in MDA-MB-231 and SUM-159 cells significantly reduces PKCα wild-type 3′UTR luciferase reporter activity ( Figure 3C ) but has no effect on the mutant-type 3′UTR luciferase reporter activity ( Figure 4D ). Collectively, these findings indicate that PKCα is a direct target of miR-200b.
Inhibiting or knocking down PKCα reduces TNBC cell migration and forced expression of PKCα impairs the inhibitory effect of miR200b on cell migration and tumor metastasis
We next wanted to determine whether downregulation of PKCα plays a role in the inhibitory effect of miR-200b on TNBC cell migration and tumor metastasis. We first used the inhibitor GO6976 that specifically inhibits PKCα and PKCβI activity. Wound healing assays showed that GO6976 treatment remarkably reduces MDA-MB-231 and SUM-159 cell migration ( Figure 4A ), suggesting that PKCα may play an important role in TNBC cell migration. To further demonstrate this point, we generated PKCα shRNA stable knockdown cells. Western blot analysis revealed that PKCα level is drastically reduced, but PKCβI and ZEB1 levels are unchanged in PKCα stable knockdown cells ( Figure 4B In striking contrast, micrometastatic foci revealed by H&E staining ( Figure 5C ), GFP immunofluorescence staining ( Figure 5D ) and 
Downregulation of PKCα by miR-200b reduces the Rho GTPase Rac1 activation
Finally, we wanted to further determine the mechanism through which PKCα downregulation by miR-200b suppresses TNBC cell migration and tumor metastasis. One mechanism of PKCα promoting cell migration is via activating the Rho GTPases Rac and Cdc42, master regulators of cell migration (41, 42) . Studies showed that Rac is overexpressed and highly activated in invasive breast cancer and inhibiting Rac activity blocks the spread of breast cancer (43, 44) . We then determined whether re-expressing miR-200b has an effect on Rac1 activation in TNBC cells. Consistent with the reduced migration observed in miR-200b expressing cells, the active Rac1 (Rac1-GTP) levels are significantly lower in MDA-MB-231-GFP-200b and SUM-159-GFP200b cells than their control counterparts ( Figure 6A and B) , indicating that miR-200b is able to reduce Rac1 activation in TNBC cells.
We next wanted to determine whether miR-200b suppresses Rac1 activation via downregulating PKCα. We found that inhibiting PKCα activity or knocking down PKCα expression both significantly reduce Rac1-GTP levels in MDA-MB-231 and SUM-159 cells (Figure 6C-E) . In sharp contrast, forced expression of PKCα in miR-200b stably expressing cells significantly increases Rac1-GTP levels ( Figure 6F ). Collectively, these results indicate that miR-200b suppresses Rac1 activation by targeting PKCα.
Discussion
Metastatic TNBC is a very aggressive subtype of breast cancer with poor prognosis and without efficient targeted therapies, underscoring the need for identifying novel targets to develop better treatment. In this study we found that miR-200 family levels are extremely low in highly migratory TNBC cells and metastatic TNBC tumors compared with other breast cancer subtypes. Moreover, we showed that ectopically expressing a single member (24, 25) . No metastatic promoting effect was observed in 4T07 cells overexpressing the miR-200b/-a/-429 group alone (25) . Instead, Gibbons et al. (23) reported that overexpression of miR-200b/-a/-429 group inhibited tumor metastasis. Of note, forced expression of miR-200b/-a/-429 group did not significantly increase the level of miR-141 (23, 25) . Together, these findings clearly show differential effects of individual miR-200 family members or two functional clusters on tumor metastasis despite their high seed sequence homology. And (ii) cancer subtype-specific effect of the miR-200 family. In this study, we found that ER+, PR+ and Her2+ human breast cancer cells and tumors had significantly higher levels of Cancer metastasis is a multistep process. When cancer cells obtain migratory and invasive capabilities, they migrate away from the primary tumor site and initiate the metastatic process (46) . Inhibition of cancer cell migration can therefore be crucial in reducing cancer metastasis. Cell migration is a dynamic process involving actin cytoskeleton reorganization mediated by actin cytoskeleton-associated proteins and their regulators (42) . In this study, we showed that PKCα is a new direct target of miR-200b and downregulation of PKCα plays a key role in the inhibitory effect of miR-200b on TNBC cell migration. Early studies showed that miR-200 may inhibit cancer cell migration by targeting certain actin cytoskeleton-associated proteins such as moesin and WAVE3 (Wiskott-Aldrich syndrome protein family member 3; 40,47,48). Our mechanistic study revealed that downregulation of PKCα by miR-200b inhibits TNBC cell migration probably through reducing the activation of Rac1, a key player in regulating actin cytoskeleton-associated proteins. Further studies are needed to determine the mechanism by which miR-200b reduces Rac1 activation. Our findings along with others indicate that miR-200 is capable of regulating actin cytoskeleton organization at multiple levels, which play critical roles in its inhibitory effect on cancer cell migration and metastasis.
The identification of PKCα as a new target of miR-200b is novel and important. In this study we found that (i) PKCα is a direct target of miR-200b; (ii) miR-200 expression is depleted in highly migratory TNBC cells and metastatic TNBC tumors; and (iii) the highest levels of PKCα are observed in highly migratory TNBC cells. These findings not only provide mechanistic insights for recent observations showing that high PKCα levels were most commonly detected in high-grade TNBC tumors (32, 33) , but also imply that our findings are potentially clinically relevant. PKCα was previously evaluated for breast cancer therapy, however only modest response to PKCα treatment was observed (49) . We believe that the modest response to PKCα treatment may be largely due to lack of preselection of recruited patients for high expression of PKCα. Taken together, the findings from this study along with others strongly support the notion that PKCα could be a very promising target for treating metastatic TNBC, and PKCα should therefore be reevaluated as a valid therapeutic target for metastatic TNBC. In addition, due to the high homology of kinase domains among PKC isozymes, targeting a specific PKC isozyme by small molecule inhibitors has been shown to be a huge challenge (50) . Our finding that miR-200b specifically targets PKCα but not other PKC isozymes provides an alternative approach for targeting PKCα. Moreover, previous studies revealed that EMT-inducing transcription factors ZEB1 and ZEB2 are direct targets of miR-200 family (15) (16) (17) (18) (19) , implicating an important role of downregulation of ZEB1/2 by miR-200 in its inhibitory effect on cancer metastasis. In this study, we found that PKCα is a direct target of miR-200b and stably expressing PKCα impairs the inhibitory effect of miR-200b on breast cancer metastasis with no significant effects on ZEB1 and E-cadherin levels. These findings provided additional evidence supporting the idea that miR-200 could repress cancer metastasis through ZEB1-independent mechanisms (40) .
In summary, we found that miR-200 level is extremely low in highly migratory TNBC cells and metastatic TNBC tumors. Stably expressing a single member (miR-200b) of miR-200 family greatly reduces TNBC cell migration and suppresses tumor metastasis. We identified PKCα as a new direct target of miR-200b and found that miR-200b suppresses TNBC cell migration and tumor metastasis by downregulating PKCα, which in turn reduces Rac1 activation. Our findings suggest that miR-200b and PKCα may represent promising targets for developing novel therapies for metastatic TNBC. Supplementary Figures 1-8 can be found at http://carcin.oxfordjournals.org/
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